HTH

SensArs is a medical equipment manufacturing company specializing in neuromodulation technology aimed at treating diabetic neuropathy. The company has developed an innovative implantable neurostimulator electrode designed to restore sensory feedback by delivering precise electrical impulses to the nerve fibers that transmit pain signals. This technology not only assists healthcare providers in enhancing patient functionality but also offers a long-term solution for pain management. SensArs' flagship system, SENSY, is particularly beneficial for patients with amputations or nerve damage, as it helps to restore natural sensations in their feet.

Lys Therapeutics is a biotechnology company focused on developing therapies for patients with neurovascular and neurodegenerative disorders. The company is centered around its lead product, Glunozumab, a monoclonal antibody that operates through a unique mechanism of action. This drug induces off-target toxicity by hyperactivating vascular and neuronal NMDA receptors, which can lead to significant disruptions in the blood-brain and blood-spinal cord barriers, as well as neuronal excitotoxicity. These effects are particularly relevant in conditions such as stroke and multiple sclerosis, where the modulation of neuroinflammation is critical for treatment.

Leuko Labs focuses on developing a non-invasive device for monitoring white blood cell counts, which is crucial for various medical situations, including chemotherapy management and the detection of severe infections. Their device, PointCheck, allows for frequent testing without the need for blood draws or laboratory infrastructure, making it more accessible for patients. This innovation aims to enhance the quality of life for immunosuppressed individuals and improve clinical outcomes by enabling healthcare providers to offer personalized treatment plans based on real-time data. By simplifying the process of white blood cell assessment, Leuko Labs contributes to more effective patient management and better survival rates.

Neurofenix is focused on enhancing rehabilitation for stroke survivors by developing an innovative upper limb rehabilitation device. This device features a hand-training controller that allows users to engage in video games, making the rehabilitation process both enjoyable and effective. By enabling patients to perform arm and hand exercises in both clinical settings and at home, Neurofenix aims to provide more autonomous and accessible therapy solutions for individuals recovering from strokes.

Endostart is a developer of innovative colonoscopy technologies aimed at improving the efficiency and safety of colonoscopy procedures. The company has created a proprietary Magnetic Balloon Anchoring Technology, which includes a magnetic balloon guide, a ferrofluid syringe, and a multi-use magnetic handpiece. These advancements are designed to assist healthcare professionals in guiding and navigating colonoscopy procedures, thereby reducing wall stress and minimizing the need for general anesthesia. Through its unique approach, Endostart seeks to enhance patient comfort and streamline the colonoscopy process.

Univercells is a company specializing in high-density, low-cost biomanufacturing solutions aimed at enhancing the production of biologics, including antibodies, proteins, and vaccines. The company leverages innovative engineering and proprietary technologies, such as single-use systems and continuous process intensification, to significantly reduce capital investments by over 75% and the cost of goods by up to 90%. Univercells offers a range of services, including scale-X hydro, scale-X carbo, and NevoLine, which support both research and development and commercial-scale production of biologics. Additionally, the company provides integrated services like equipment confirmation, capacity and facility design, and bioprocess excellence, facilitating the scalability of cell and gene therapy manufacturers from clinical trials to commercial manufacturing. Through its commitment to making biologics more accessible and affordable, Univercells addresses critical global health challenges.

AirGo specializes in developing non-invasive medical respiratory sensors that enable real-time monitoring of minute ventilation and breath dynamics. Their innovative device consists of a wearable, miniaturized recorder unit paired with a medical-grade holter, designed to be worn over the floating ribs of patients during both rest and normal activities. This technology excels in long-term live and remote monitoring, capturing data during daily activities, sleep sessions, and exercise. The platform processes data in real-time using proprietary algorithms that provide live alerts and detailed diagnostic reports, facilitating quicker and more precise diagnoses for physicians. Additionally, AirGo's algorithms deliver enhanced insights into sleep disorders compared to traditional polysomnography and home sleep testing methods. The company is committed to integrating its technology into a cloud platform that complies with GDPR and HIPAA regulations, ensuring large-scale deployment while maintaining patient confidentiality.